Open Access3-Bromopyruvate Attenuates Experimental Pulmonary Hypertension via Inhibition of Glycolysis
Author(s) -
YunLong Zhang,
Rui Zhang,
Yifan Shen,
Kai-Yue Huang,
Yangyang He,
Junhan Zhao,
ZhiCheng Jing
Publication year - 2018
Publication title -
american journal of hypertension
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.009
H-Index - 136
eISSN - 1941-7225
pISSN - 0895-7061
DOI - 10.1093/ajh/hpy191
Subject(s) - medicine , glycolysis , lactate dehydrogenase , pulmonary hypertension , right ventricular hypertrophy , pulmonary artery , hexokinase , pharmacology , pyruvate kinase , mitochondrion , apoptosis , oxidative phosphorylation , biochemistry , metabolism , enzyme , biology
The shift of metabolism from mitochondrial oxidative phosphorylation to glycolysis and mitochondria binding partner of hexokinase are features common to cancer. These have been seen in pulmonary hypertension (PH) as well. An inhibitor of hexokinase 2 (HK 2), the small molecule 3-bromopyruvate (3-BrPA) is an incredibly powerful and swift-acting anticancer agent. However, whether it could be of potential benefit to PH has still been unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom